Madrigal Pharmaceuticals, Inc.
MDGL Healthcare Biotechnology
Madrigal Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $958.4 million, up 432.1% from fiscal 2024. In the quarter to June 2026, revenue grew 71.2%, EPS fell 32.9%, free cash flow grew 140.5% and total debt rose 187.9%, each against the same quarter a year earlier.
Follow MDGL
Madrigal Pharmaceuticals, Inc. (MDGL) Altman Z-score
Madrigal Pharmaceuticals, Inc.'s Altman Z-score for fiscal 2025 is 10.48, in the safe zone (above 2.99).
Altman Z-score, annual
Embed this chart
Annual newest first
| Period | Altman Z-score | Change (points) |
|---|---|---|
| FY2025 | 10.48 | (0.38) |
| FY2024 | 10.85 | — |
How fiscal 2025’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Working capital / total assets | 0.74 | — | 0.89 | |
| Retained earnings / total assets | (1.66) | — | −2.32 | |
| EBIT / total assets | (0.24) | — | −0.79 | |
| Market value of equity / total liabilities | 19.89 | — | 11.93 | |
| Sales / total assets | 0.76 | — | 0.76 | |
| Altman Z-score | Safe zone | 10.48 | ||
| Z″ Variant for non-manufacturing and asset-light companies (drops the sales/assets term, uses book equity) | Distress zone | −1.18 | ||
Z and Z″ put Madrigal Pharmaceuticals, Inc. in different zones: safe zone by Z, distress zone by Z″.
How the Altman Z-score works
Z = 1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets (Altman, 1968). The market value of equity is the close on the last trading day of the fiscal year times weighted basic shares.
Z″ = 6.56 × working capital ÷ total assets + 3.26 × retained earnings ÷ total assets + 6.72 × EBIT ÷ total assets + 1.05 × book equity ÷ total liabilities (Altman, Hartzell and Peck, 1995), the variant for non-manufacturing and asset-light companies.
| Zone | Z | Z″ |
|---|---|---|
| Safe zone | above 2.99 | above 2.60 |
| Grey zone | 1.81–2.99 | 1.10–2.60 |
| Distress zone | below 1.81 | below 1.10 |
Not worked out for banks, insurers and REITs, whose balance sheets the model does not describe, nor when a figure is missing or there is no share price in the week to the fiscal year end.
Altman Z-score against peers
| Company | Altman Z-score |
|---|---|
| KRYS Krystal Biotech, Inc. compare | 39.0× |
| KYMR Kymera Therapeutics, Inc. compare | 23.2× |
| TECH Bio-Techne Corp compare | 15.5× |
| CORT Corcept Therapeutics Incorporated compare | 14.1× |
| MDGL Madrigal Pharmaceuticals, Inc. | 10.5× |
| BMRN BioMarin Pharmaceutical Inc. compare | 5.7× |
| SMMT Summit Therapeutics PLC compare | 0.9× |
| IBRX ImmunityBio, Inc. compare | −10.2× |
| PCVX Vaxcyte, Inc. compare | — |
What Altman Z-score is
The Altman Z-Score weighs working capital, retained earnings, operating profit, market value and sales against assets and debts to gauge the risk of distress.
1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets